Prevention of ornithine cytotoxicity by nonpolar side chain amino acids in retinal pigment epithelial cells
Prevention of ornithine cytotoxicity by nonpolar side chain amino acids in retinal pigment epithelial cells
复制标题
DOI:
10.1167/iovs.03-0403
复制
发表时间:
2003-11-01
影响因子:
4.4
通讯作者:
Ito, S
中科院分区:
文献类型:
--
作者:
Nakauchi, T;Ando, A;Ito, S
PURPOSE. To investigate the effect of amino acids on ornithine cytotoxicity in ornithine-delta-aminotransferase (OAT)- deficient human retinal pigment epithelial (RPE) cells as an in vitro model of gyrate atrophy (GA) of the choroid and retina.METHODS. RPE cells were treated with 0.5 mM 5-fluoromethyl-ornithine (5-FMOrn), a specific and irreversible OAT inhibitor. OAT-deficient RPE cells were incubated with 10 mM ornithine in the presence of 20 mM of 1 of 18 amino acids or 10 mM 2-amino-2-norbornane-carboxylic acid (BCH), a conventional inhibitor of the amino acid transporter system L. Ornithine cytotoxicity and cytoprotective effects of each amino acid was evaluated with a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) colorimetric assay 72 hours after treatment with ornithine in OAT-deficient RPE cells. Ornithine incorporation into RPE cells was evaluated using DL-[C-14] ornithine.RESULTS. An MTT colorimetric assay revealed that small and large zwitterionic amino acids, but not acidic or basic amino acids, decreased ornithine cytotoxicity in OAT-deficient RPE cells. Incorporation of DL-[C-14] ornithine by RPE cells decreased to 79% of the control level after incubation for 48 hours with 20 mM leucine, the most effective cytoprotective amino acid. Further, BCH prevented ornithine cytotoxicity in a dose-dependent manner. Both light and heavy chains of L-type amino acid transporter (LAT)-1, LAT2, y(+)LAT1, and 4F2hc were expressed in RPE cells.CONCLUSIONS., The present results demonstrate that L-type amino acid transporter(s) may be involved in protection against ornithine cytotoxicity in human RPE cells. Thus, amino acid transportation in RPE cells may be a good target for a new therapy for GA as well as other kinds of chorioretinal degeneration.